You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for SUBVENITE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for SUBVENITE

Average Pharmacy Cost for SUBVENITE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
SUBVENITE 25 MG TABLET 69102-0301-01 0.02750 EACH 2025-01-22
SUBVENITE 100 MG TABLET 69102-0319-01 0.04060 EACH 2025-01-22
SUBVENITE TAB START KT(ORANGE) 69102-0300-01 14.39490 EACH 2025-01-22
SUBVENITE 150 MG TABLET 69102-0150-06 0.05997 EACH 2025-01-22
SUBVENITE 200 MG TABLET 69102-0320-01 0.07339 EACH 2025-01-22
SUBVENITE 25 MG TABLET 69102-0301-01 0.02741 EACH 2024-12-18
SUBVENITE 100 MG TABLET 69102-0319-01 0.04236 EACH 2024-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for SUBVENITE (Lamotrigine)

Overview of SUBVENITE

SUBVENITE, also known as lamotrigine, is an antiepileptic drug used in the treatment of epilepsy and as a mood stabilizer for bipolar disorder. It is indicated for adjunctive therapy in patients aged 2 years and older with various types of seizures, and for the maintenance treatment of bipolar I disorder in adults[1][3][5].

Market Demand and Usage

Clinical Indications

SUBVENITE is widely used for several clinical indications, including:

  • Adjunctive therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome in patients aged 2 years and older.
  • Monotherapy conversion for patients aged 16 years and older with partial-onset seizures.
  • Maintenance treatment of bipolar I disorder to delay the occurrence of mood episodes in adults[1][3][5].

The diverse range of indications contributes to a steady and significant demand for the drug.

Pricing and Cost Considerations

Current Pricing

The cost of SUBVENITE varies based on the dosage and the pharmacy. Here are some current price points:

  • 25 mg oral tablet: Around $108 for a supply of 100 tablets.
  • 100 mg oral tablet: Around $143.51 for a supply of 100 tablets.
  • 150 mg oral tablet: Around $149.88 for a supply of 100 tablets.
  • 200 mg oral tablet: Around $164.89 for a supply of 100 tablets[2].

Generic Alternatives

A generic version of lamotrigine is available, significantly reducing the cost. For example, generic lamotrigine can cost as low as $26.80 for 100 tablets of the 25 mg dosage[2].

Coupons, Copay Cards, and Patient Assistance

To make the drug more accessible, various coupons, copay cards, and patient assistance programs are available. These can significantly reduce the out-of-pocket costs for patients[2].

Market Trends and Projections

Drug Price Inflation

According to Vizient's summer Pharmacy Market Outlook, the overall drug price inflation rate for pharmaceuticals is projected to be 3.81% in 2025. This trend suggests that prices for SUBVENITE and other medications may increase, although the specific impact on SUBVENITE is not detailed in the report[4].

Impact of Generic Competition

The availability of generic lamotrigine has a significant impact on the pricing of SUBVENITE. Generic competition typically drives down the prices of brand-name drugs, making them more competitive in the market. This trend is likely to continue, influencing the pricing strategy for SUBVENITE[2].

Expanding Indications and Market Growth

While SUBVENITE's indications are well-established, the broader trend of expanding indications for other medications (such as GLP-1 agents) could indirectly influence market dynamics. However, SUBVENITE's specific market growth will be more directly tied to its established use cases and the presence of generic alternatives[4].

Patient and Provider Perspectives

Patient Access and Affordability

Patient access to SUBVENITE is crucial, and affordability is a significant factor. The availability of savings cards, copay cards, and patient assistance programs helps make the drug more accessible. However, the ongoing price inflation in the pharmaceutical market could pose challenges for patients in the future[2].

Provider Considerations

Healthcare providers need to balance the therapeutic benefits of SUBVENITE with its cost implications. Given the drug's efficacy and the availability of generic options, providers often opt for the more affordable generic version to manage patient care costs effectively[2][3].

Regulatory and Safety Considerations

Safety Warnings

SUBVENITE carries serious safety warnings, including the risk of life-threatening skin rashes such as Stevens-Johnson syndrome and toxic epidermal necrolysis. These warnings are critical for both patients and healthcare providers to consider when prescribing and using the drug[1].

Contraindications and Precautions

The drug is contraindicated in patients with hypersensitivity to lamotrigine or its ingredients. Additionally, there are specific dosing guidelines and considerations to prevent adverse reactions, which healthcare providers must carefully follow[1][3].

Key Takeaways

  • Market Demand: SUBVENITE has a steady demand due to its multiple clinical indications.
  • Pricing: The drug's cost varies, but generic alternatives significantly reduce the price.
  • Market Trends: Drug price inflation and generic competition are key factors influencing the market.
  • Patient and Provider Perspectives: Affordability and therapeutic benefits are crucial considerations.
  • Regulatory and Safety Considerations: Serious safety warnings and contraindications must be carefully managed.

FAQs

What are the primary uses of SUBVENITE?

SUBVENITE is used as adjunctive therapy for various types of seizures and as a mood stabilizer for bipolar I disorder[1][3][5].

How much does SUBVENITE cost?

The cost of SUBVENITE varies by dosage, but a supply of 100 tablets of the 25 mg dosage can cost around $108. Generic versions are significantly cheaper, starting at $26.80 for 100 tablets[2].

Are there any serious safety warnings associated with SUBVENITE?

Yes, SUBVENITE carries warnings for life-threatening skin rashes such as Stevens-Johnson syndrome and toxic epidermal necrolysis. It should be discontinued at the first sign of rash unless clearly not drug-related[1].

What are the contraindications for SUBVENITE?

SUBVENITE is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients[1].

How does the availability of generic lamotrigine affect the market for SUBVENITE?

The availability of generic lamotrigine significantly reduces the cost and makes the drug more competitive, influencing the pricing strategy for SUBVENITE[2].

Sources

  1. Subvenite Starter Kits - Subvenite Starter Kits help simplify treatment initiation for you and your patients in a more structured way than is offered by multiple weekly prescriptions. [Subvenite]
  2. Subvenite Prices, Coupons, Copay Cards & Patient Assistance - The cost for Subvenite 25 mg oral tablet is around $108 for a supply of 100 tablets. [Drugs.com]
  3. Lamotrigine: Uses, Interactions, Mechanism of Action - Lamotrigine is an antiepileptic drug belonging to the phenyltriazine class. [DrugBank]
  4. Vizient projects drug price inflation at 3.81% - Vizient, Inc. released its summer Pharmacy Market Outlook estimating the 2025 overall drug price inflation rate for pharmaceuticals at 3.81%. [Vizient]
  5. Subvenite Oral: Uses, Side Effects, Interactions, Pictures, Warnings - Lamotrigine is used alone or with other medications to prevent and control seizures. [WebMD]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.